Research ArticleOriginal Article

Preoperative ultrasound combined with routine blood tests in predicting the malignant risk of pancreatic cystic neoplasms

Xiuchao Wang, Junjin Wang, Xi Wei, Lihui Zhao, Bo Ni, Zekun Li, Chuntao Gao, Song Gao, Tiansuo Zhao, Jian Wang, Weidong Ma, Xiao Hu and Jihui Hao
Cancer Biology & Medicine October 2022, 19 (10) 1503-1516; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0258

References

  1. 1.↵
    2. Kromrey ML,
    3. Bülow R,
    4. Hübner J,
    5. Paperlein C,
    6. Lerch MM,
    7. Ittermann T, et al.
    Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018; 67: 138–45.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Nagtegaal ID,
    3. Odze RD,
    4. Klimstra D,
    5. Paradis V,
    6. Rugge M,
    7. Schirmacher P, et al.
    The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76: 182–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Neoptolemos JP,
    3. Urrutia R,
    4. Abbruzzese J,
    5. Büchler MW
    2. Basturk O,
    3. Reid MD,
    4. Adsay NV.
    Pathologic Classification and Biological Behavior of Pancreatic Neoplasia. In Neoptolemos JP, Urrutia R, Abbruzzese J, Büchler MW (eds): Pancreatic Cancer. New York, NY: Springer New York. 2017; 1–37.
  4. 4.↵
    2. Ayoub F,
    3. Davis AM,
    4. Chapman CG.
    Pancreatic Cysts-An Overview and Summary of Society Guidelines, 2021. JAMA. 2021; 325: 391–2.
    OpenUrl
  5. 5.↵
    2. Jones MJ,
    3. Buchanan AS,
    4. Neal CP,
    5. Dennison AR,
    6. Metcalfe MS,
    7. Garcea G.
    Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology. 2013; 13: 436–42.
    OpenUrlPubMed
  6. 6.↵
    2. Singhi AD,
    3. McGrath K,
    4. Brand RE,
    5. Khalid A,
    6. Zeh HJ,
    7. Chennat JS, et al.
    Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2018; 67: 2131–41.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Asaoka T,
    3. Miyamoto A,
    4. Maeda S,
    5. Tsujie M,
    6. Hama N,
    7. Yamamoto K, et al.
    Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016; 16: 434–40.
    OpenUrlCrossRef
  8. 8.
    2. Chen Y,
    3. Yan H,
    4. Wang Y,
    5. Shi Y,
    6. Dai G.
    Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7: 753.
    OpenUrlPubMed
  9. 9.
    2. Kumarasamy C,
    3. Sabarimurugan S,
    4. Madurantakam RM,
    5. Lakhotiya K,
    6. Samiappan S,
    7. Baxi S, et al.
    Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2019; 98: e14834.
  10. 10.
    2. Goh BKP,
    3. Tan DMY,
    4. Chan CY,
    5. Lee SY,
    6. Lee VTW,
    7. Thng CH, et al.
    Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms? J Surg Oncol. 2015; 112: 366–71.
    OpenUrl
  11. 11.↵
    2. Gao X,
    3. Pan Y,
    4. Han W,
    5. Hu C,
    6. Wang C,
    7. Chen L, et al.
    Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas. Cancer Biol Med. 2021; 18: 283–97.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Stone RL,
    3. Nick AM,
    4. McNeish IA,
    5. Balkwill F,
    6. Han HD,
    7. Bottsford-Miller J, et al.
    Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366: 610–8.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Li X,
    3. Xu H,
    4. Gao P.
    ABO blood group and diabetes mellitus influence the risk for pancreatic cancer in a population from China. Med Sci Monit. 2018; 24: 9392–8.
    OpenUrl
  14. 14.↵
    2. Iodice S,
    3. Maisonneuve P,
    4. Botteri E,
    5. Sandri MT,
    6. Lowenfels AB.
    ABO blood group and cancer. Eur J Cancer. 2010; 46: 3345–50.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Kimura W,
    3. Moriya T,
    4. Hirai I,
    5. Hanada K,
    6. Abe H,
    7. Yanagisawa A, et al.
    Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas. 2012; 41: 380–7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Chu LC,
    3. Singhi AD,
    4. Haroun RR,
    5. Hruban RH,
    6. Fishman EK.
    The many faces of pancreatic serous cystadenoma: Radiologic and pathologic correlation. Diagn Interv Imaging. 2017; 98: 191–202.
    OpenUrl
  17. 17.↵
    2. Chen F,
    3. Liang JY,
    4. Zhao QY,
    5. Wang LY,
    6. Li J,
    7. Deng Z, et al.
    Differentiation of branch duct intraductal papillary mucinous neoplasms from serous cystadenomas of the pancreas using contrast-enhanced sonography. J Ultrasound Med. 2014; 33: 449–55.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Vege SS,
    3. Ziring B,
    4. Jain R,
    5. Moayyedi P.
    American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148: 819–22; quize12-3.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Scheiman JM,
    3. Hwang JH,
    4. Moayyedi P.
    American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148: 824–48.e22.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Tanaka M,
    3. Fernández-Del Castillo C,
    4. Kamisawa T,
    5. Jang JY,
    6. Levy P,
    7. Ohtsuka T, et al.
    Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17: 738–53.
    OpenUrlCrossRefPubMed
  21. 21.↵
    European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018; 67: 789–804.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Morelli L,
    3. Guadagni S,
    4. Borrelli V,
    5. Pisano R,
    6. Di Franco G,
    7. Palmeri M, et al.
    Role of abdominal ultrasound for the surveillance follow-up of pancreatic cystic neoplasms: a cost-effective safe alternative to the routine use of magnetic resonance imaging. World J Gastroenterol. 2019; 25: 2217–28.
    OpenUrl
  23. 23.↵
    2. Wang W,
    3. Zhang L,
    4. Chen L,
    5. Wei J,
    6. Sun Q,
    7. Xie Q, et al.
    Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Biomed Rep. 2015; 3: 43–50.
    OpenUrl
  24. 24.↵
    2. Carmicheal J,
    3. Patel A,
    4. Dalal V,
    5. Atri P,
    6. Dhaliwal AS,
    7. Wittel UA, et al.
    Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Biochim Biophys Acta Rev Cancer. 2020; 1873: 188318.
  25. 25.↵
    2. Kern SE,
    3. Hruban RH,
    4. Hidalgo M,
    5. Yeo CJ.
    An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther. 2002; 1: 607–13.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Nougaret S,
    3. Mannelli L,
    4. Pierredon MA,
    5. Schembri V,
    6. Guiu B.
    Cystic pancreatic lesions: from increased diagnosis rate to new dilemmas. Diagn Interv Imaging. 2016; 97: 1275–85.
    OpenUrl
  27. 27.↵
    2. Farrell JJ.
    Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver. 2015; 9: 571–89.
    OpenUrl
  28. 28.↵
    2. Coussens LM,
    3. Werb Z.
    Inflammation and cancer. Nature. 2002; 420: 860–7.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Lan C,
    3. Li X,
    4. Wang X,
    5. Hao J,
    6. Ren H.
    A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms. Cancer Biol Med. 2018; 15: 70–8.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Wolpin BM,
    3. Chan AT,
    4. Hartge P,
    5. Chanock SJ,
    6. Kraft P,
    7. Hunter DJ, et al.
    ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009; 101: 424–31.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    2. Amundadottir L,
    3. Kraft P,
    4. Stolzenberg-Solomon RZ,
    5. Fuchs CS,
    6. Petersen GM,
    7. Arslan AA, et al.
    Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41: 986–90.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Hofmann BT,
    3. Stehr A,
    4. Dohrmann T,
    5. Güngör C,
    6. Herich L,
    7. Hiller J, et al.
    ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Clin Cancer Res. 2014; 20: 6117–26.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Tuppy H,
    3. Staudenbauer WL.
    Microsomal incorporation of N-acetyl-D-galactosamine into blood group substance. Nature. 1966; 210: 316–7.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Grivennikov SI,
    3. Greten FR,
    4. Karin M.
    Immunity, inflammation, and cancer. Cell. 2010; 140: 883–99.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Dall’olio F.
    Protein glycosylation in cancer biology: an overview. Clin Mol Pathol. 1996; 49: M126–35.
    OpenUrlFREE Full Text
  36. 36.↵
    2. Bhattathiri VN.
    Relation of erythrocyte and iron indices to oral cancer growth. Radiother Oncol. 2001; 59: 221–6.
    OpenUrlPubMed
  37. 37.↵
    2. Sheng X,
    3. Chen W,
    4. Xu Y,
    5. Lin F,
    6. Cao H.
    Higher mean corpuscular hemoglobin concentration is associated with worse prognosis of hepatorenal syndrome: a multicenter retrospective study. Am J Med Sci. 2022; 363: 25–32.
    OpenUrl
  38. 38.↵
    2. Adris N,
    3. Chua ACG,
    4. Knuiman MW,
    5. Divitini ML,
    6. Trinder D,
    7. Olynyk JK, et al.
    A prospective cohort examination of haematological parameters in relation to cancer death and incidence: the Busselton Health Study. BMC Cancer. 2018; 18: 863.
    OpenUrl
  39. 39.↵
    2. Tsantes AE,
    3. Bonovas S,
    4. Travlou A,
    5. Sitaras NM.
    Redox imbalance, macrocytosis, and RBC homeostasis. Antioxid Redox Signal. 2006; 8: 1205–16.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords